Pacritinib: First Approval

2022/05/01 by Yvette N. Lamb · 20 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Myeloproliferative Neoplasms: Diagnosis and Treatment #Chronic Myeloid Leukemia Treatments #Kruppel-like factors research

paper · doi:10.1007/s40265-022-01718-y

Cited by

• A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. [europepmc]
• Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review. [europepmc]
• Simultaneous green TLC determination of nirmatrelvir and ritonavir in the pharmaceutical dosage form and spiked human plasma. [europepmc]
• Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology. [europepmc]
• Rapid Hepatomegaly From Ruxolitinib Discontinuation Syndrome. [europepmc]
• Synthesis and clinical application of new drugs approved by FDA in 2022. [europepmc]
• Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects. [europepmc]
• Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity. [europepmc]
• Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers. [europepmc]
• Back-Pocket Optimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent EPHA2/GAK Kinase Inhibitors. [europepmc]
• Interleukin-1 Receptor-Associated Kinase 1 in Cancer Metastasis and Therapeutic Resistance: Mechanistic Insights and Translational Advances. [europepmc]
• Treatment Strategies Used in Treating Myelofibrosis: State of the Art. [europepmc]
• FDA-approved drugs featuring macrocycles or medium-sized rings. [europepmc]
• Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma. [europepmc]
• Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials. [europepmc]
• Exploring Macrocyclic Chemical Space: Strategies and Technologies for Drug Discovery. [europepmc]
• Application of Free Energy Perturbation (FEP) Methodology for Predicting the Binding Affinity of Macrocyclic JAK2 Inhibitor Analogues of Pacritinib. [europepmc]
• Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database. [europepmc]
• Cytokine Landscapes, Immune Dysregulation, and Treatment Perspectives in Philadelphia-Negative Myeloproliferative Neoplasms: A Narrative Review. [europepmc]
• Revisiting Janus kinases as molecular drug targets for rheumatic diseases. [europepmc]